Kim MacMartin-Moglia
Company:
InterVenn Biosciences
Title:
Vice President of Business Development
Category:
Life Sciences
Award Year:
2023
Profile
Kim MacMartin-Moglia is the Vice President of Business Development at InterVenn Biosciences, a life science company pioneering glycoproteomics to improve human health. During her tenure at InterVenn, Ms. MacMartin-Moglia has developed relationships with partner companies to enable the discovery of novel glycoproteomic biomarker signatures utilized for early diagnosis, disease prognosis and therapeutic response. In addition, Ms. MacMartin-Moglia has developed a team of business development professionals to support the company's rapid growth and evolving business development needs. The company is developing a robust pipeline of proprietary tests and diagnostic applications that apply novel glycoproteomics insights to clinical decision-making.
Prior to joining InterVenn, Ms. MacMartin-Moglia was the Director of Business Development at Werfen, where she was responsible for in/out-licensing of IP, negotiating key supplier relationships and managing their IP portfolio with outside counsel. Before Werfen, Ms. MacMartin-Moglia held other business development/marketing roles related to precision medicine at Prometheus Laboratories and Quest Diagnostics. Ms. MacMartin-Moglia received her MBA with emphases in Finance in Marketing at University of San Diego and her Bachelor's degree in Biochemistry and Cellular Biology from the University of California at San Diego.
Areas of Expertise
Business Development, Biomarker Discovery, Diagnostics, Therapeutics, Pharma Partnering.
Company Overview
InterVenn is a clinical technology company unlocking the value of glycoproteomics for the development of transformational healthcare solutions. The glycoproteome is a source of life-critical information about human biology that has the potential to significantly improve patient outcomes, but it has remained inaccessible due to its vast complexity. InterVenn is pioneering a new AI-powered platform to decode the potential of the glycoproteome at clinically meaningful scale for the first time in history. The company has developed a platform capable of producing a robust pipeline of powerful clinical applications, ranging from early disease screening to diagnostics and potentially therapeutics. Founded by Nobel Laureate Dr. Carolyn Bertozzi, world-class scientist and distinguished professor Dr. Carlito Lebrilla and leading AI/ML expert Aldo Carrascoso, InterVenn will contribute to making the new era of personalized, predictive, and preventative care a reality.